Spectrometers are widely used in the pharmaceutical industry to measure differences between experimental samples. Spectroscopic methods such as Fourier-transform infrared spectroscopy (FTIR) and circular dichroism (CD) are often used for characterizing protein secondary structures with inherent drawbacks such as limited sample dynamic range, excipient interference, and poor sensitivity. Historically, these limitations were accepted due to a lack of better options. Microfluidic Modulation Spectroscopy (MMS) is a new automated IR technology that overcomes most of the limitations associated with FTIR and CD. It can be used for a wide range of applications from formulation development of mAb-based biotherapeutics to robust measurements of ADCs, AAVs, mRNA, proteins, and enzymes. This robust technology is available exclusively by way of the first generation AQS3pro and second generation Apollo systems, powered by MMS technology. Download this infographic to read about four key benefits that distinguish MMS from traditional IR methods.
